GlycoMimetics Current Ratio 2012-2025 | CBIO
GlycoMimetics current ratio from 2012 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| GlycoMimetics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2025-03-31 |
$0.01B |
$0.00B |
2.29 |
| 2024-12-31 |
$0.01B |
$0.01B |
1.92 |
| 2024-09-30 |
$0.02B |
$0.00B |
3.62 |
| 2024-06-30 |
$0.02B |
$0.00B |
5.48 |
| 2024-03-31 |
$0.03B |
$0.01B |
6.28 |
| 2023-12-31 |
$0.04B |
$0.01B |
6.41 |
| 2023-09-30 |
$0.05B |
$0.01B |
8.14 |
| 2023-06-30 |
$0.06B |
$0.01B |
9.19 |
| 2023-03-31 |
$0.07B |
$0.01B |
10.10 |
| 2022-12-31 |
$0.05B |
$0.01B |
5.71 |
| 2022-09-30 |
$0.05B |
$0.01B |
6.95 |
| 2022-06-30 |
$0.06B |
$0.01B |
6.85 |
| 2022-03-31 |
$0.08B |
$0.01B |
6.06 |
| 2021-12-31 |
$0.09B |
$0.01B |
7.68 |
| 2021-09-30 |
$0.10B |
$0.01B |
10.78 |
| 2021-06-30 |
$0.12B |
$0.01B |
11.74 |
| 2021-03-31 |
$0.13B |
$0.01B |
12.33 |
| 2020-12-31 |
$0.14B |
$0.01B |
11.13 |
| 2020-09-30 |
$0.15B |
$0.01B |
14.83 |
| 2020-06-30 |
$0.15B |
$0.01B |
15.81 |
| 2020-03-31 |
$0.16B |
$0.01B |
14.78 |
| 2019-12-31 |
$0.16B |
$0.01B |
14.84 |
| 2019-09-30 |
$0.18B |
$0.01B |
16.75 |
| 2019-06-30 |
$0.19B |
$0.01B |
17.54 |
| 2019-03-31 |
$0.20B |
$0.01B |
23.88 |
| 2018-12-31 |
$0.21B |
$0.01B |
24.22 |
| 2018-09-30 |
$0.22B |
$0.01B |
34.57 |
| 2018-06-30 |
$0.23B |
$0.01B |
33.10 |
| 2018-03-31 |
$0.25B |
$0.01B |
28.30 |
| 2017-12-31 |
$0.13B |
$0.01B |
15.56 |
| 2017-09-30 |
$0.11B |
$0.01B |
17.44 |
| 2017-06-30 |
$0.12B |
$0.01B |
21.97 |
| 2017-03-31 |
$0.04B |
$0.01B |
7.78 |
| 2016-12-31 |
$0.04B |
$0.01B |
6.40 |
| 2016-09-30 |
$0.05B |
$0.01B |
8.59 |
| 2016-06-30 |
$0.06B |
$0.01B |
8.95 |
| 2016-03-31 |
$0.04B |
$0.01B |
6.95 |
| 2015-12-31 |
$0.05B |
$0.01B |
6.10 |
| 2015-09-30 |
$0.05B |
$0.01B |
7.95 |
| 2015-06-30 |
$0.06B |
$0.01B |
8.94 |
| 2015-03-31 |
$0.05B |
$0.00B |
11.54 |
| 2014-12-31 |
$0.06B |
$0.01B |
8.69 |
| 2014-09-30 |
$0.06B |
$0.01B |
13.14 |
| 2014-06-30 |
$0.07B |
$0.00B |
18.66 |
| 2014-03-31 |
$0.06B |
$0.00B |
21.83 |
| 2013-12-31 |
$0.01B |
$0.00B |
2.14 |
| 2013-09-30 |
$0.01B |
$0.00B |
3.13 |
| 2013-06-30 |
$0.00B |
|
0.00 |
| 2013-03-31 |
$0.00B |
|
0.00 |
| 2012-12-31 |
$0.00B |
|
0.00 |
| 2012-09-30 |
$0.00B |
|
0.00 |
| 2011-12-31 |
$0.03B |
$0.02B |
1.73 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
